| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
Kadsurin does not have a single defined pharmacological target. As a lignan with antioxidant activity, its primary mechanism involves scavenging reactive oxygen species and inducing antioxidant enzymes in the liver. It significantly decreases CCl₄-induced lipid peroxidation products, indicating protection against oxidative damage. The compound may also modulate oxidative stress pathways, protect liver function, and support mitochondrial health. Its unique lignan structure contributes to its bioactivity and potential as a lead compound in natural product-based drug discovery.
|
|---|---|
| ln Vitro |
In vitro, Kadsurin has antioxidant activity and induces enzymes capable of scavenging oxygen radical species. It significantly decreases CCl₄-induced lipid peroxidation products, such as TBA-RS, conjugated dienes, and fluorescent products. As a lignan, it may also have antitumor promoting or chemopreventive activity. However, specific IC₅₀ values or detailed activity data is not provided in the available sources.
|
| ln Vivo |
In vivo, Kadsurin significantly decreases CCl₄-induced lipid peroxidation products in the liver of mice. It induces enzymes capable of scavenging oxygen radical species in the liver. The compound protects liver function and supports mitochondrial health. It may be valuable as an antitumor promoter or chemopreventive agent. However, specific in vivo dosing and efficacy data is not detailed in the available sources.
|
| Enzyme Assay |
For antioxidant compounds, standard cell-free assays include DPPH radical scavenging, ABTS radical cation decolorization, and ferric reducing antioxidant power (FRAP) assays. These assays involve incubating the compound with free radical-generating systems and measuring the reduction in oxidative products. Lipid peroxidation inhibition can be measured using thiobarbituric acid reactive substances (TBARS) assays.
|
| Cell Assay |
For antioxidant compounds, standard cellular assays involve treatment of hepatocytes or other cell lines with the test compound followed by exposure to oxidative stress (e.g., CCl₄, H₂O₂). Cell viability, reactive oxygen species (ROS) levels, lipid peroxidation (MDA), and antioxidant enzyme activities (SOD, CAT, GPx) are measured.
|
| Animal Protocol |
For in vivo evaluation of hepatoprotective compounds, standard animal models include CCl₄-induced liver injury in mice or rats. The compound is typically administered orally or intraperitoneally prior to CCl₄ challenge. Liver function markers (ALT, AST), lipid peroxidation products, antioxidant enzyme activities, and liver histology are assessed.
|
| ADME/Pharmacokinetics |
Detailed pharmacokinetic data for Kadsurin is not provided in the available sources. The compound has a molecular weight of 458.50 and formula C₂₅H₃₀O₈. As a lignan with moderate lipophilicity, it would be expected to have reasonable oral absorption. Comprehensive PK studies would be required for therapeutic development.
|
| Toxicity/Toxicokinetics |
Detailed toxicology data for Kadsurin is not provided in the available sources. As a naturally occurring compound, it may have a favorable safety profile at moderate doses. However, comprehensive toxicological evaluation would be required for therapeutic development. The compound is for research use only and not for therapeutic applications.
|
| References | |
| Additional Infomation |
Kadsurin (-)- is a tannin. It functions as a metabolite. Kadsurin has been reported to be found in Kadsura ananosma, Kadsura interior, and other organisms with relevant data.
Kadsurin is a naturally occurring compound found in the stems of Kadsura heteroclita. It has antioxidant activity and induces enzymes capable of scavenging oxygen radical species in the liver. The compound significantly decreases CCl₄-induced lipid peroxidation products. It may be valuable as an antitumor promoter or chemopreventive agent. No regulatory approval has been identified. |
| Molecular Formula |
C25H30O8
|
|---|---|
| Molecular Weight |
458.50100
|
| Exact Mass |
458.194
|
| CAS # |
51670-40-7
|
| PubChem CID |
171064
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.549
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
33
|
| Complexity |
673
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C[C@@H]1CC2=CC(=C(C(=C2C3=C(C4=C(C=C3[C@@H]([C@@H]1C)OC(=O)C)OCO4)OC)OC)OC)OC
|
| InChi Key |
QUGMSTJBNZWXQS-SQHYZVFZSA-N
|
| InChi Code |
InChI=1S/C25H30O8/c1-12-8-15-9-17(27-4)22(28-5)24(29-6)19(15)20-16(21(13(12)2)33-14(3)26)10-18-23(25(20)30-7)32-11-31-18/h9-10,12-13,21H,8,11H2,1-7H3/t12-,13-,21-/m1/s1
|
| Chemical Name |
[(9R,10R,11R)-3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.02,7.014,18]nonadeca-1(19),2,4,6,12,14(18)-hexaen-11-yl] acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1810 mL | 10.9051 mL | 21.8103 mL | |
| 5 mM | 0.4362 mL | 2.1810 mL | 4.3621 mL | |
| 10 mM | 0.2181 mL | 1.0905 mL | 2.1810 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
